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Introduction: Although smoking cessation is strongly indicated by international guidelines as
an effective therapeutic tool for patients with COPD and Asthma, a large proportion of them
do not quit smoking and they are regarded as a "difficult" target group.
Aim: To study the effectiveness of an intensive smoking cessation program in smokers with
COPD and asthma under real-life conditions.
Methods: 166 smokers with COPD, 120 smokers with asthma and 1854 control smokers at-
tended the smoking cessation program in the out-patient patient Smoking Cessation Clinic of
the Pulmonary Department in Athens University. Continuous Abstinence Rate (CAR) was eval-
uated in 3, 6, 9 and 12 months after the target quit date.
Results: Short-term CAR (in 3 months) was 49.4% for COPD smokers, 51.7% for asthmatic
smokers and 48.0% for the control group of smokers. 12 months after the initial visit the
CAR was 13.9%, 18.3% and 15.9%, respectively. No statistically significant differences between
groups at any study period were found. Smokers with good compliance with the program had
higher long-term CAR after 12 months: 37.7% in COPD smokers, 40.0% in asthmatic smokers and
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578 C. Gratziou et al.Conclusion: The results support the view that smokers with respiratory obstructive airway dis-
eases of any severity should be offered an intensive smoking cessation program with regular
and long-term follow-up. This will help them to achieve high abstinence rates and prevent re-
lapses.
Published by Elsevier Ltd.Introduction
Cigarette smoking is a major preventable risk factor for
respiratory obstructive airway diseases (ROAD), mainly
represented by Chronic Obstructive Pulmonary Disease
(COPD) and asthma [1].
COPD is a significant and growing cause of morbidity
and mortality with smoking being recognized as its most
important causative factor [2,3]. It is estimated that
by 2020, it will become the 3rd leading cause of death
[4]. COPD current smokers have higher prevalence of
respiratory symptoms, greater annual rate of decline
in FEV1, and higher death rates for COPD than nonsmokers
[2,5].
Active smoking as a risk factor for developing asthma
remains to be elucidated, although epidemiological and
family studies have indicated that genes predisposing to
asthma interact with environmental tobacco smoke (ETS)
exposure in early life. [1,6] Asthmatic smokers have more
severe asthma symptoms, increased risk of asthma attacks
and exacerbations, a shift to inflammatory phenotype from
eosinophilia towards neutrophilia, increased risk of death,
and a degree of steroid-resistance with significant effect to
treatment response [7,8].
Smoking cessation is the most important therapeutic
intervention in patients at all stages of COPD, since it is
the only intervention that slows down the disease pro-
gression and improves respiratory symptoms [2,9]. In
asthmatic patients, smoking cessation improves lung
function, asthma symptoms, and treatment outcome. It
also significantly improves the asthma specific quality of
life score [7,10,11].
Although smokers with respiratory complaints seem
more motivated to quit smoking than those with no such
complaints [12], a large proportion of them e especially
patients with severe COPD e do not quit smoking and
require support [13]. Usually, respiratory patients develop
“tolerance” to repeated quit advice [6]. They also have
relatively high prevalence of depression or low mood
[14,15], higher nicotine dependence score [16,17] and
more fear of weight gain [6]. Furthermore in advanced
stages of COPD, quality of life is low and the smoking pa-
tient considers cigarettes as one of the few things left that
improve quality of life [6].
The aim of our study was to evaluate the effectiveness
of an intensive smoking cessation program, in real world
clinical practice with currently approved pharmacological
treatment and counseling in smokers with ROAD (COPD and
Asthma). As primary endpoint, we considered the short-
term Continuous Abstinence Rates (CARs) in 3 months after
Target Quit Date (TQD), while as a secondary endpoint, we
considered the long-term abstinence 6, 9 and 12 months
after TQD.Method
This was a retrospective, observational, real life, study that
recruited smokers from the out-patient Smoking Cessation
Clinic of the Pulmonary Department in Athens University.
The study conducted from 2009 to 2012 and was approved
by the ethical committee of the hospital.
Subjects e study population
During the study period, 2140 adults Caucasian smokers,
selected from smokers who voluntarily visited the Smoking
Cessation Clinic, were enrolled in the study. All participants
were >18 years, self-motivated to stop smoking and were
smoking 10 cigarettes per day for at least 5 years. 286 had
a history of chronic respiratory obstructive airway disease
previously diagnosed by a physician: 166 of current smokers
had COPD and 120 had a long time history of persistent
allergic asthma. Smokers with COPD (persistent airway
obstruction FEV1/FVC <70%) were classified according to
the GOLD classification into 4 stages (stage I: FEV1 >80%
pred, stage II: FEV1 50%e80% pred, stage III: FEV1 30%e50%,
stage IV: FEV1 <30%) [18]. Stages III and IV were combined
for statistical analysis due to a small number of COPD pa-
tients at stage IV (only 2 subjects). Asthmatic smokers had a
history of well controlled asthma, as it is defined according
to GINA guidelines [19]. Patients with unstable or undiag-
nosed respiratory disease were excluded from the study.
The control group consisted of smokers without any
respiratory symptoms and no history of pulmonary, car-
diovascular or psychiatric disease.
Study protocol
The study protocol included a first baseline visit, four
weekly follow-ups and finally a follow-up visit every 4
weeks up to 12 weeks. Then, a long-term follow-up was
scheduled every 3 months up to 12 months.
Baseline visit
A thorough personal and clinical assessment was held by a
respiratory physician, specialized in smoking cessation
during the first visit. The duration of the initial visit was
about 60 min.
Initially, every participant completed specific question-
naires regarding (a) smoking habits, (b) nicotine depen-
dence assessment performed by the Fagerstro¨m test for
nicotine dependence [20] (FTND score 1e10), (c) motiva-
tion and self-efficacy to quit smoking by asking and rating
the following three questions i) How difficult is quitting
smoking? ii) How much do you want to stop smoking? iii)
How confident do you feel that your attempt will be suc-
cessful? Assessment score in a scale from 1 to 10 [6].
Table 2 Stages of severity of disease in smokers with
COPDa (by GOLDb classification).
Disease severity Patients number (%)
Stage I (FEV1%
c pred. >80%) 49 (29.5%)
Stage II (FEV1% pred. 50% to 80%) 44 (26.5%)
Stage III & IV (FEV1% pred. <50%) 73 (44.0%)
a COPD: Chronic obstructive pulmonary disease.
b GOLD: Global initiative for chronic Obstructive Lung Disease.
c FEV1: Forced expiratory volume in 1 s.
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nostic and Statistical Manual of Mental Disorders-IV e
withdrawal scale) [21].
The smoking status was confirmed by measuring the
exhaled carbon monoxide (CO) using CO analyzer [22].
Smokers were allocated to one of four smoking cessation
treatments based on their preference, the physician’s
choice according to international guidelines, the smoker’s
medical history, and other concomitant medication
[6,23e25]. The 4 treatments were : Nicotine Replacement
Therapy (patch, inhaler, gum, sublingual tablet or any
combination) for 12 weeks, Bupropion SR for 8 weeks
(150 mg once daily for the first week and 150 mg bd for the
rest 8 weeks), and Varenicline for 12 weeks (0.5 mg once
daily for the first 3 days, 0.5 mg bd for 4e7 day and 1 mg bd
for the rest 11 weeks). A Target Quit Date (TQD) was set
between 10 and 15 days after the baseline visit.
Follow-up visits
Nine follow-up visits were scheduled per protocol: once
every week for the first month, then one every 4 weeks up to
12 weeks (3 months) and finally one every three months (at
month 6, 9 and 12) after the TQD. If a smoker had missed a
visit, a telephone contact was made to re-schedule the
appointment, as soon as possible. Between the regular visits,
the smoker could make an additional contact. In every visit,
the DSM IV withdrawal scale was completed, while smoking
status was confirmed by exhaled CO e with CO 10 ppm to
indicate that the subject was an active smoker. Body weight
and blood pressure were also recorded. Psychological and
behavioral interventions were given at every follow-up visit,
according to personal needs to prevent relapses, reinforce
the quit effort, and discuss possible withdrawal symptoms. A
physician and a psychologist with a special training on
smoking cessation [26] provided an individual personalized
counseling with duration of at least 30 min.
Statistical analysis
Continuous variables are presented as mean  sd. Chi
square test, t-test or analysis of variance were used to
evaluate baseline differences in demographic and smoking
history variables. Chi square test was used to assess dif-
ferences in abstinence rates between groups (COPD,
asthma and control smokers). Two-tailed p values of <0.05
were considered statistically significant.Table 1 Demographics and smoking attitudes characteristics of
COPDa (n Z 166) Asthma (n Z
Age 55.4 (9.3) 41.9 (10.0)
Cigarettes/day 38.0 (18.1) 32.7 (15.3)
Packs/year 66.7 (38.3) 37.0 (29.7)
FDNTc 7.1 (1.8) 7.0 (2.1)
DSM-IVd 15.0 (7.8) 14.5 (7.4)
Motivation scale 8 9
Data are expressed as mean  sd.
a COPD: chronic obstructive pulmonary disease.
b ROAD: Respiratory obstructive airway diseases (COPD and asthma)
c FDNT: Fagerstro¨m Test for Nicotine Dependence.
d DSM-IV: Diagnostic and Statistical Manual of Mental Disorders IV.Results
Patient’s data
Baseline characteristics of the study population are pre-
sented in Table 1.
Between smokers with ROAD and control smokers, a
statistically significant difference in age (p < 0.001), packs
per year (p Z 0.001) and DSM-IV (p Z 0.049) was found.
Smokers with COPD and asthma had higher mean age,
smoked more cigarettes (packs per year), and had higher
DSM-IV score. Age and smoking history (packs per year)
were statistically significantly higher in COPD group than in
asthmatics (p < 0.001). DSM-IV score was similar between
those two groups. Nicotine dependence was severe
(FDNT > 7) in all groups of smokers with no statistically
significant difference among them. Motivation and self-
confidence to quit was not different in between the study
groups.
The distribution between male and female was almost
equal in both groups of smokers with respiratory disease
and control group of smokers (48.6% and 51.4% were men in
smokers with asthma-COPD and control group, respec-
tively). No statistically significant difference in the pro-
portion of two genders was found neither in smokers with
respiratory diseases (p Z 0.565) nor in control smokers
(pZ 0.090). Severity stages for COPD are shown in Table 2.
CAR in the whole (intention-to-treat) study
population
CAR in the intention-to-treat (IT) study population was
calculated based on the total number of subjects, who
attended the program even for one or two visits. Table 3the study population.
120) ROADb (n Z 286) Control (n Z 1854)
49.7 (11.8) 45.7 (10.4)
36.0 (17.0) 33.3 (14.4)
54.5 (37.8) 43.6 (27.0)
7.1 (1.9) 7.1 (2.0)
14.7 (7.6) 13.4 (7.6)
8.5 8
.
Table 3 Continuous Abstinence Rate at 3 months (end of pharmacological treatment) and at 6, 9, 12 months after Target Quit
Date (TQD) in smokers with ROAD vs control group and in smokers with COPD vs asthmatic smokers in the whole study
population.
CARa, n(%) 3 months 6 months 9 months 12 months
Control group 890 (48.0%) 549 (29.6%) 454 (24.5%) 295 (15.9%)
Smokers with ROADb 145 (50.7%) 89 (31.2%) 81 (28.4%) 45 (16.0%)
p-Value 0.425 0.632 0.191 0.999
Smokers with COPDc 82 (49.4%) 48 (28.9%) 44 (25.9%) 23 (13.9%)
Smokers with asthma 63 (51.7%) 41 (34.2%) 37 (30.8%) 22 (18.3%)
p-Value 0.796 0.414 0.434 0.389
a CAR: Continuous Abstinence Rate.
b ROAD: Respiratory Obstructive Airway Disease (COPD and asthma).
c COPD: Chronic Obstructive Pulmonary Disease.
580 C. Gratziou et al.presents the short-term CAR (at 3 months after TQD) and
the long-term CAR (at 6, 9, and 12 months following TQD).
Smokers were considered as quitters, if they did not smoke
at all after the TQD.
Short-term CAR was 49.4% for the COPD patients, 51.7%
for the asthmatic smokers, and 48.0% for the controls.
These differences were not statistically significant between
the smokers with COPD and the asthmatics (p Z 0.796) or
between the smokers with ROAD and the controls
(p Z 0.425) (Table 3).
The long-term CAR was also not statistically significantly
different between COPD and asthmatic smokers or between
smokers with ROAD and control group of smokers at 6, 9,
and 12 months (Table 3).
No statistically significant differences in the abstinence
rates at any time during the study between men and women
among the three groups of smokers (control, COPD, asthma)
were found.
CAR according to compliance to the program
Smokers were considered to have good compliance to the
intensive program if they had at least 4 visits during for the
first treatment period, more than 4 weeks of pharmaco-
logical treatment and 3 regular visits during the follow-up
study period up to 12 months.
Table 4 presents the short-term and long-term CAR for
smokers with good compliance. CAR at 3 months wereTable 4 Continuous Abstinence Rate at 3 months (end of pharm
Date (TQD) in smokers with ROAD vs control group and in smo
compliance to the program.
CARa, n(%) 3 months 6 m
Control smokers 890 (56.8%) 549
Smokers with ROADb 144 (59.3%) 89
p-Value 0.500 0.3
Smokers with COPDc 82 (59.4%) 48
Smokers with asthma 62 (57.9%) 41
p-Value 0.919 0.9
a CAR: Continuous Abstinence Rate.
b ROAD: Respiratory obstructive airway disease (COPD and asthma).
c COPD: Chronic Obstructive Pulmonary Disease.comparable with the IT population with no statistically
differences neither between smokers with ROAD and con-
trols (59.3% and 56.8% respectively, p Z 0.500) nor be-
tween COPD and asthmatics (59.4% and 57.9% respectively,
p Z 0.919). However, CAR at 12 months was more than
double in all study groups for the smokers with good
compliance.
Fig. 1a and b present CAR in smokers with COPD and
asthma with respect to the duration of attendance to the
program with compliance to treatment (1e3 weeks, 4e7
weeks and >8 weeks). The longer the attendance with
better compliance to treatment was, the higher the absti-
nence rates were. After 1 year, CAR were 6.3% (n Z 1) vs
54.1% (nZ 20) in COPD smokers and 11.1% (nZ 2) vs 54.8%
(n Z 17) in asthmatic smokers, who took medication
treatment for less than 3 weeks and more than 8 weeks,
respectively.
Comparison between treatment arms is not presented,
as the treatment was not randomly selected, but person-
alized according to the needs and doctors choice.
CAR among COPD smokers according to disease
severity (GOLD stages)
Table 5 presents the abstinence rates in COPD smokers with
respect to disease severity (defined by GOLD 2010). The
CAR for stages I and II of COPD are comparable with those
for controls in all study periods. COPD smokers with severeacological treatment) and at 6, 9, 12 months after Target Quit
kers with COPD vs asthmatic smokers in smokers with good
onths 9 months 12 months
(52.1%) 454 (46.6%) 295 (39.3%)
(56.4%) 80 (51.9%) 45 (39.5%)
61 0.249 0.999
(55.2%) 43 (50.6%) 23 (37.7%)
(56.9%) 37 (51.4%) 22 (40.0%)
49 0.999 0.950
Figure 1 a. CAR at 3, 6, 9 and 12 months after TQD in
smokers with COPD. b. CAR at 3, 6, 9 and 12 months after TQD
in smokers with asthma.
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short-term abstinence rates at 3, 6, and 9 months. After 1
year, the rates remain high and similar to those of smokers
with milder COPD stages and controls.
Discussion
In the present observational study, we examined the
effectiveness of an intensive, smoking cessation program in
patients with ROAD under real life conditions. Medical and
psychological counseling combined with the approved first
line pharmacological treatment [6,23e25] against nicotine
dependence were included in the program with regular
follow-up visits for a year.
The results of this real life study showed high short-term
CAR in patients with ROAD that was not different from CAR
in smokers without a disease. The abstinence rates were
comparable with the CAR referred in previous randomized
control clinical studies for patients with COPD [27e29]. To
the best of our knowledge, there are not many studies
looking for the abstinence rates in asthmatic smokers.Table 5 Continuous Abstinence Rates (CAR) at 3, 6, 9 and
12 months after Target Quit Date (TQD) for COPD smokers
with good compliance to the program according to GOLD
stages of the disease.
CARa 3 months 6 months 9 months 12 months
Stage I 24 (55.8%) 13 (46.4%) 12 (42.9%) 9 (39.1%)
Stage II 23 (60.5%) 9 (47.4%) 6 (33.3%) 5 (33.3%)
Stages III & IV 35 (61.4%) 26 (65.0%) 25 (64.0%) 9 (39.1%)
a CAR: Continuous Abstinence Rate.In a double-blind, placebo-controlled multicenter study
by Tashkin et al. investigating the efficacy of varenicline in
patients with mild to moderate COPD, an abstinence rate of
42.3% is referred at the end of the treatment and 18.6%
through weeks 9e52 [29]. Tonnesen et al. report 14.0% CAR
for COPD patients after 1 year, using nicotine sublingual
tablets [28] and Wagena et al. 28.0% at 26th week using
bupropion SR [27]. The higher but no statistically different
abstinence rates in our smoker patients compared with
controls may be due to the fact that our patients were
highly motivated to quit smoking. Because they regularly
visited the chest clinic for their usual care of the disease,
the same team of doctors repeatedly and strongly advised
them to quit smoking.
It is well known that the most difficult issue in the pro-
cess of quitting is to remain abstinent from smoking. The
smoker’s progress during the first period of a quit attempt is
very important for the long-term abstinence [30]. The in-
tensity of a smoking cessation program and the compliance
to the medication treatment are important factors as well.
Our results suggest that regular and close follow-up during
the first period of a quit attempt is very crucial for the long-
term abstinence. The regular follow-up visits during the
first 3 months are very important for a successful quit
attempt: the physician can enhance the motivation, help
and support the smoker to overcome personal fears by
discussing behavioral changes and withdrawal symptoms
due to nicotine addiction, check the compliance to treat-
ment and possible side effects, control and prevent factors
that can lead a smoker to relapse. Our study showed that if
smokers who want to quit use medication adequately in
time (more than 8 weeks) can achieve a very high CAR.
Previously reported meta-analyses [6,23] have documented
a strong relationship between abstinence and the duration
of each clinic visit, the number of sessions, and total con-
tact time in population of smokers from general population.
This seems to be more important in smokers with chronic
illness, such as smokers with respiratory diseases, that are
more reluctant to try to overcome difficulties in quitting, as
they are less motivated, more depressed, have frequently
other comorbidities, and take concomitant medications
[14,15,17,20]. For all these reasons, they need a close
follow-up and medical support.
Another interesting finding of our study is that high CAR
was observed in all COPD smokers irrespectively of the
severity of their disease. Even severe COPD smokers (stages
III and IV) can have the same abstinence rates as smokers at
the earlier stages of the disease (I and II) and as the control
group of smokers, if they can follow an intensive supportive
program. Our results are relevant to those referred by
Jimenez-Ruiz et al. [31] as far as the effectiveness and
safety of drug treatment for smoking cessation in smokers
with severe and very severe COPD with high continuous
abstinence rates (48.5%) in 24 weeks after the quit date.
Special care and more intensive interventions are sug-
gested to increase success rate of smoking cessation among
smoking patients with chronic respiratory disease [32]. In a
Swedish study, COPD patients that smoked were hospital-
ized for 11 days with the aim of getting them to quit
smoking. They were prescribed NRT and offered counseling
for 1 h daily. The quit rate after 1 year was 52.0% for hos-
pitalization and 7.0% for usual care [33]. Our intensive
582 C. Gratziou et al.smoking cessation program with the regular follow-up visits
within an out-patient clinic seems to give high smoking
cessation efficacy and is more easily applicable and
acceptable by the majority of smoker patients. Further-
more, the hospitalization may cost more for the health
system.
Compared with the general population, smokers with
respiratory airway obstructive diseases are considered as a
difficult target group. One of the reasons may be the high
prevalence of depression [14,15,34], which is indepen-
dently associated with smoking [35] and failure to give it up
[36]. Depression is also one of the withdrawal symptoms
that predicts relapse to smoking [37]. The prevalence of
depression in COPD patients with severe airway obstruction
(FEV1 < 50%) was 25.0% and had 2.5 times greater risk of
depression than healthy smokers [15]. Similar findings for
asthmatic patients show that individuals with asthma re-
ported more symptoms of depression and especially among
those patients with severe asthma [14]. Smoking in these
situations may be helpful as a kind of self-medication that
controls emotions. Relapsing after a quit attempt may be a
way to escape from depressive mood [6,38]. In our study,
although we had significant differences in DSM-IV score at
baseline between smokers with ROAD and controls with
comparable score between smokers with COPD and asthma,
we did not find differences in the short-term or long-term
CAR. It seems that the strong health motivation, com-
bined with the intensive medical and personal support
during a quit attempt can give high abstinence rates in 3, 6,
and 12 months, even in patients with severe respiratory
disease.
The degree of nicotine dependence has been found to
predict outcomes in quit attempts [16,17,20]. An epide-
miological, multicenter, population-based study showed
that smokers with COPD were more dependent on nicotine
than healthier smokers (FTND scores 4.7 vs 3.1, respec-
tively; pZ 0.001). The same study reported that only 10.0%
of healthy smokers had high dependence, whereas 28.0% of
smokers with COPD were highly dependent [20]. Higher
levels of nicotine dependence were also found among ad-
olescents with asthma and especially among those with
higher symptom severity. This explains the greater number
of unsuccessful smoking cessation attempts, compared to
those without asthma [17]. However, our study population
did not show any difference at the nicotine dependence
among smokers with COPD or asthma and the control
smokers. High nicotine dependence score (FTND score > 7)
was observed in all study groups and was higher than the
average score showed in other studies in which the profile
of smokers attending a smoking cessation service was
described [39,40]. The high nicotine dependence scores did
not affect the efficacy of our intensive smoking cessation
program neither in control group of smokers nor in the
respiratory patients group.
Most of the participants of our study were highly moti-
vated to quit smoking and more willing to quit, more
confident for their effort as they had previously visited the
same chest clinic for their routine disease care and thus the
same doctor repeatedly advised them to quit smoking. The
behavioral support was adjusted to each individual smoker
personal life and medical history. Medication treatment
was not randomized, so comparisons of treatment armscould not be performed, but prescribed with respect to
patient’s needs and will. Despite these limitations, this
study provides important information for the effectiveness
of a smoking cessation program in patients with respiratory
diseases compared to control smokers under real world
circumstances, reflecting the routine clinical practice. The
study results can help health physicians recognize that
smoking cessation is a mandatory first medical intervention
and thus, advise smoker patients with chronic respiratory
disease to quit smoking.
In conclusion, our results showed that it is crucial for
smokers with asthma or COPD of any severity to attend an
intensive smoking cessation program with regular and long-
term follow-up e this will help them achieve high short-
term and long-term abstinence rates and avoid relapses.
Regular attendance with frequent follow-up visits mainly
for the first three months are important and the combina-
tion of medical counseling with individual behavioral sup-
port and pharmaceutical treatment can increase
abstinence rates through reinforcing the quit effort and
overcoming possible withdrawal symptoms. Doctor’s opti-
mistic approach and more motivational tools to increase
the patient compliance can be helpful. Quitting smoking is
the healthiest intervention to affect the natural progres-
sion, the treatment response and quality of life in all res-
piratory patients.
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